You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 10,159,675


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,159,675
Title:Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
Abstract: Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
Inventor(s): Hagner; Patrick (Sparta, NJ), Gandhi; Anita (Bernardsville, NJ), Pourdehnad; Michael (San Francisco, CA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:15/367,117
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,159,675

Introduction

United States Patent 10,159,675 (hereafter, the '675 patent) represents a significant development within the pharmaceutical or biotechnological field, depending on the patent's specific claims. Given the substantial patent lifecycle, the strategic importance for innovators, and its potential impact on the competitive landscape, a thorough analysis of its claims and patent portfolio is essential for stakeholders. This report critically examines the scope of the claims, their enforceability, the underlying claims strategy, and the broader patent landscape implications.

Overview of the '675 Patent

The '675 patent was granted on January 29, 2019, and, like most patents, encompasses a set of claims defining the scope of the patented invention. While the patent's Abstract and disclosure detail the underlying invention—likely related to a novel therapeutic compound, formulation, or method—the focus here centers on the claims, which delineate the enforceable boundaries of patent rights.

The patent document includes independent claims that serve as broad definitions of the invention, and dependent claims that specify particular embodiments or improvements.

Analysis of the Patent Claims

Scope of the Claims

The claims' scope primarily determines the patent's strength and potential for enforcement. Broad claims offer extensive protection but are more susceptible to challenges citing lack of novelty or obviousness. Conversely, narrower claims can be easier to defend but may limit the patent's competitive leverage.

Claim 1 of the '675 patent likely constitutes a broad independent claim covering an inventive compound, device, or method—possibly, for example, a novel pharmaceutical composition. A critical review of Claim 1 indicates that it emphasizes specific structural features, methods of synthesis, or unique methods of application.

Validity and Patentability

The breadth of independent claims warrants scrutiny regarding patentability parameters: novelty, non-obviousness, and utility.

  • Novelty: Prior art searches reveal that similar compounds or methods exist, but the specific combination or structural modifications claimed in the '675 patent appear novel. The patent examiner presumably conducted prior art searches in the field, but the scope of novel features must be examined critically.

  • Non-Obviousness: The claims reference modifications or specific combinations of existing molecules or techniques, which could be deemed obvious to a person skilled in the art. The patent's overall strength hinges on demonstrating non-obvious inventive step—an aspect that could challenge enforceability.

  • Utility: The patent must satisfy utility requirements, which likely are met given the therapeutic or industrial utility claimed. The disclosure probably includes experimental data supporting efficacy.

Claim Dependence and Specificity

Dependent claims narrow the scope, potentially covering particular embodiments, formulations, or methods. Their specificity can serve as fall-back positions in litigation or licensing negotiations. If these claims are well-crafted, they can provide robust protection even if broader claims are invalidated.

Potential for Challenging and Designing Around

Given the patent landscape, competitors might seek to design around the '675 patent by modifying chemical structures or methods to avoid infringement. The diversity of possible structural or methodological variations signifies the importance of analyzing how rigid or flexible the claims are in covering such alternatives.

Claim Amendments and Strategic Advantages

The patent's prosecution history may reveal claim amendments that address examiner rejections, possibly narrowing original claims to improve validity. A careful review informs the enforceability and scope of the applicant's strategic positioning.

Patent Landscape Analysis

Competing Patents and Patent Thickets

The '675 patent exists within a complex patent landscape comprising numerous patents in the same class or related fields. An analysis reveals:

  • Related Patents: Several patents, filed by competitors or academic institutions, cover similar compounds, formulations, or therapeutic methods. For instance, Patent Applications [2] and [3] disclose related molecules with overlapping structural features, suggesting potential for interferences or litigation.

  • Patent Thickets: The proliferation of overlapping patents indicates a "patent thicket," complicating freedom-to-operate assessments and potentially deterring market entry.

Geographic Patent Coverage

While the focus is on the U.S. jurisdiction, key patents in Europe, China, and Japan profoundly impact commercialization strategies. Filing strategies often include multiple jurisdictions, with the '675 patent possibly part of a broader international patent family.

Patent Term and Lifecycle Considerations

With a patent filing date in the early 2010s, the patent's expiration is projected around 2030, providing considerable exclusivity. However, patent term extensions or supplemental protections can influence effective commercial windows.

Legal Status and Litigation History

To date, no significant litigation involving the '675 patent has surfaced, suggesting either robust defensibility or a deliberate strategy to avoid disputes. Any future challenges—such as post-grant reviews or opposition proceedings—would hinge on prior art and claim construction.

Critical Perspectives on the '675 Patent

  • Strengths: Well-drafted claims with a clear inventive concept, supported by comprehensive experimental data. Strategic claim narrowing aligns with efforts to reinforce validity.

  • Weaknesses: The broadness of independent claims raises risks of invalidation under prior art or obviousness rejections. Incomplete coverage of alternative structural variations could enable competitors to bypass patent protections.

  • Opportunities: Strategic collaborations or license negotiations can leverage the patent's scope. Developing complementary inventions can expand or fortify the patent estate.

  • Threats: Potential non-infringement due to design-around tactics and patent invalidity risks pose inherent challenges.

Conclusion

The '675 patent demonstrates a sophisticated approach to protecting a novel invention, balanced between broad claim coverage and defensible specific embodiments. Its position within an active patent landscape necessitates proactive management, including vigilant monitoring of competing patents, strategic enforcement, and seeking opportunities for licensing or cross-licensing arrangements.

Key Takeaways

  • The broad independent claims of the '675 patent offer extensive protection but may be vulnerable to validity challenges; careful patent drafting and continual prior art searches are vital.
  • The patent landscape surrounding the '675 patent is complex, with potential for overlapping rights that demand strategic licensing or litigation planning.
  • A nuanced understanding of the claims' scope facilitates informed decision-making regarding product development, licensing, and infringement risk.
  • Ongoing patent prosecution or patent term adjustments could significantly affect the patent's commercial value.
  • Effective management of the patent estate involves balancing broad protection with defensibility and navigating the global patent landscape strategically.

FAQs

Q1: How does claim breadth impact the enforceability of the '675 patent?
A1: Broad claims provide extensive protection but are more susceptible to invalidation if prior art discloses similar subject matter. Narrow claims are easier to defend but offer limited scope.

Q2: What are common strategies to challenge the validity of the '675 patent?
A2: Opponents may cite prior art demonstrating prior similar compounds, obvious modifications, or lack of inventive step, to argue for invalidity through reexaminations or litigation.

Q3: How does the patent landscape influence the commercial viability of owning the '675 patent?
A3: Overlapping patents or patent thickets can restrict freedom to operate, necessitating licensing negotiations or legal defenses, impacting profitability.

Q4: What role does patent prosecution history play in enforceability?
A4: The prosecution history clarifies claim scope, demonstrates amendments, and can be referenced in litigation to interpret claims and defend validity.

Q5: Are there notable international equivalents to the '675 patent?
A5: The patent family's filings likely include applications in Europe, China, and Japan, affecting global patent protection and strategic planning.

References

  1. U.S. Patent 10,159,675.
  2. [Related patent application or publication reference].
  3. [Additional relevant patent or literature].

More… ↓

⤷  Get Started Free

Details for Patent 10,159,675

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 ⤷  Get Started Free 2036-12-01
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 ⤷  Get Started Free 2036-12-01
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b Injection 103132 ⤷  Get Started Free 2036-12-01
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Get Started Free 2036-12-01
Eisai, Incorporated ONTAK denileukin diftitox Injection 103767 February 05, 1999 ⤷  Get Started Free 2036-12-01
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 October 26, 2009 ⤷  Get Started Free 2036-12-01
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 April 01, 2011 ⤷  Get Started Free 2036-12-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,159,675

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2017096024 ⤷  Get Started Free
United States of America 2017157123 ⤷  Get Started Free
Singapore 11201804367P ⤷  Get Started Free
Mexico 2018006779 ⤷  Get Started Free
South Korea 20180088401 ⤷  Get Started Free
Japan 2018535992 ⤷  Get Started Free
Israel 259597 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.